<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;table cellspacing="0" cellpadding="2" border="0" summary="This table shows the date, time, and location of the meeting" style="WIDTH: 643px; HEIGHT: 93px" id="schedule"&gt;     &lt;tbody&gt;         &lt;tr&gt;             &lt;th valign="top" bgcolor="#cccccc" align="left" style="WIDTH: 71px" id="a1"&gt;Center&lt;/th&gt;             &lt;th valign="top" bgcolor="#cccccc" align="left" style="WIDTH: 158px" id="a2"&gt;Date&lt;/th&gt;             &lt;th valign="top" bgcolor="#cccccc" align="left" style="WIDTH: 172px" id="a3"&gt;Time&lt;/th&gt;             &lt;th valign="top" bgcolor="#cccccc" align="left" style="WIDTH: 238px" id="a4"&gt;Location&lt;/th&gt;         &lt;/tr&gt;         &lt;tr&gt;             &lt;td valign="top" headers="a1" style="WIDTH: 71px; HEIGHT: 74px"&gt;CDER&lt;/td&gt;             &lt;td valign="top" headers="a2" style="WIDTH: 158px; HEIGHT: 74px"&gt;July 26,  2011&lt;br /&gt;             &amp;nbsp;&lt;/td&gt;             &lt;td valign="top" headers="a3" style="WIDTH: 172px; HEIGHT: 74px"&gt;8:00 a.m. to 5:30  p.m.&lt;br /&gt;             &amp;nbsp;&lt;/td&gt;             &lt;td valign="top" headers="a4" style="WIDTH: 238px; HEIGHT: 75px"&gt;FDA White Oak  Campus&lt;br /&gt;             Building 31&lt;br /&gt;             The Great Room (Rm. 1503)&lt;br /&gt;             White Oak Conference  Center&lt;br /&gt;             10903 New Hampshire Avenue&lt;br /&gt;             Silver Spring,  Maryland&lt;/td&gt;         &lt;/tr&gt;     &lt;/tbody&gt; &lt;/table&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;The committee will discuss presentations by the Office of Generic Drugs (OGD) on bioequivalence issues and quality standards relative to narrow therapeutic index (NTI) drug products as a class.  In response to feedback during the April 13, 2010, Advisory Committee for Pharmaceutical Science and Clinical Pharmacology (ACPS-CP) meeting, the committee will further discuss the definition and list of NTI drugs, as well as proposed bioequivalence standards for these products.  The committee will also receive awareness presentations relevant to OGD&amp;rsquo;s ongoing focus on quality and safety of generic drug products.  Presentations will outline current activities seeking to better understand the impact of formulation and quality on the performance of generic drug products and current thinking related to potential regulatory pathways for these issues.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Meeting Materials&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Background Material&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt;     &lt;li&gt;&lt;a target="" href="[!--$wcmUrl('link','UCM240583')--]"&gt;2011 Meeting Materials, Pharmaceutical Science and Clinical  Pharmacology Advisory Committee&lt;/a&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Public Participation Information&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;Interested persons may present data, information, or views, orally or in  writing, on issues pending before the committee.&lt;/p&gt; &lt;ul class="noindent"&gt;     &lt;li&gt;Written submissions may be made to the contact person on or before July 19, 2011.&lt;/li&gt;     &lt;li&gt;Oral presentations from the public will be scheduled between approximately 11 a.m. to 12 noon, and 4:30 p.m. to 5 p.m.  Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before July 12, 2011.&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;Time allotted for each presentation may be limited.  If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.  The contact person will notify interested persons regarding their request to speak by July 13, 2011.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt;     &lt;li&gt;Yvette Waples, Pharm.D.&lt;br /&gt;     Center for Drug  Evaluation and Research&lt;br /&gt;     Food and Drug Administration&lt;br /&gt;     10903 New Hampshire  Avenue&lt;br /&gt;     WO31-2417&lt;br /&gt;     Silver Spring, MD 20993-0002&lt;br /&gt;     Phone:  301-796-9001&lt;br /&gt;     Fax: 301-847-8533&lt;br /&gt;     E-mail:&amp;nbsp;&lt;a href="mailto:ACPS-CP@fda.hhs.gov"&gt;ACPS-CP@fda.hhs.gov&lt;/a&gt;&lt;/li&gt; &lt;/ul&gt; &lt;ul&gt;     &lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;     1-800-741-8138&lt;br /&gt;     (301-443-0572  in the Washington DC area)&lt;br /&gt;     Code: 3014512539&lt;br /&gt;     Please call the Information  Line for up-to-date information on this meeting&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.  Therefore, you should always check the agency&amp;rsquo;s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt; &lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.  FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Yvette Waples at (301) 796-9001 at least 7 days in advance of the meeting.&lt;/p&gt; &lt;p&gt;Information regarding ground transportation, airport  information, lodging, driving directions and visitor parking, and security can  be accessed at: &lt;a target="" href="[!--$wcmUrl('link','UCM241740')--]"&gt;Public Meetings at the FDA White Oak Campus&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;FDA is committed to the orderly conduct of its  advisory committee meetings. Please visit our Web site at &lt;a target="" href="[!--$wcmUrl('link','UCM111462')--]"&gt;Public Conduct During FDA Advisory Committee Meetings&lt;/a&gt; for procedures on public conduct  during advisory committee meetings&lt;/p&gt; &lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5  U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
